Ballys (NYSE:BALY) reported quarterly sales of $314.80 million which beat the analyst consensus estimate of $312.09 million by 0.87 percent. This is a 169.93 percent increase over sales of $116.62 million the same period last year.
OPKO Health’s BioReference Laboratories Announces Readiness For COVID-19 Testing If Omicron COVID-19 Variant Emerges In U.S
BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), announced COVID-19 testing preparedness for the Omicron Variant. BioReference's PCR diagnostic tests for SARS-CoV-2 COVID-19 are based on